Lincoln Pharma's Q4 financial report shows strong growth and receives 'Hold' call from MarketsMOJO

Lincoln Pharmaceuticals, a smallcap company in the pharmaceutical industry, has recently declared its financial results for the quarter ending March 2024. The company's stock has been given a 'Hold' call by MarketsMOJO, a leading financial analysis platform.

According to the financial report, Lincoln Pharma has shown a positive performance in the quarter, with a score of 8 out of 10. This is a slight decrease from the previous quarter, where the company had a score of 10. However, the company's financials for the quarter have shown promising growth.

One of the key highlights of the financial report is the Profit After Tax (PAT) for the quarter, which has grown by 48.1% year on year, reaching Rs 18.60 crore. This is a significant increase and indicates a strong performance by the company. The near-term trend for PAT is also positive, which is a good sign for investors.

Another positive aspect of the financial report is the Net Sales for the quarter, which has grown by 26.70% year on year, reaching Rs 142.49 crore. This shows a steady growth in the company's sales and a positive trend in the near term.

Overall, the financial results for the quarter ending March 2024 have been positive for Lincoln Pharmaceuticals. With a 'Hold' call from MarketsMOJO, investors can keep a close eye on the company's performance in the coming months.